Current treatment strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

Current Drug Discovery Technologies

Volumn 4, Issue 2, 2007, Pages 133-140

  Mishra, Poonam ^a   Younossi, Zobair M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETAINE; CANNABINOID RECEPTOR 1 ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; CLOFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; METFORMIN; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIBUTRAMINE; TELMISARTAN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ARTICLE; CELL PROTECTION; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; FATTY LIVER; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; KINESIOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FATTY DEGENERATION; LIVER TOXICITY; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT PLANNING; WEIGHT CONTROL;

ANTIOXIDANTS; BIOPSY; DISEASE PROGRESSION; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; LIVER; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548447932     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016307781483469     Document Type: Article

References (79)

1. Ludwig J., Viggiano T.R., McGill D.B.: Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hither to unnamed disease. Mayo Clin. Proc. 55, 434-438, (1980).
2. Chitturi S., Farrell G., George J.: Non-alcoholic steatohepatitis in the Asia-Pacific Region: Future Shock? J. Gastroenter. Hepatol. 19, 368-374, (2004).
3. Chitturi C., George J.: NAFLD/NASH is notjust a "Western" problem: Some perspectives on NAFLD/NASH from the east. In: Fatty Liver Disease: NASH and related disorders. Eds. GC Farell, J George. P Hall, AJ Mccullough. Blackwell Publishing, Oxford; pp. 219-228, (2005).
4. Marchesini G., Forlani G.: NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35, 497-9, (2002).
5. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395, (2002).
6. Matteoni C.A., Younossi Z.M., Gramlich T,. Boparai N., Liu Y., McCullough A.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419, (1999).
7. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J., Powell L.: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11, 74-80, (1990).
8. Falck-Ytter Y., Younossi Z.M., Marchesini G., et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Seminars in Liver Disease 21(1), 17-26, (2001).
9. Yousseff W.I, McCullough A.J.: Steatohepatitis in obese individuals. Best Pract. Res. Clin. Gastoenterol 16, 733-47, (2002).
10. Lee R.G.: Nonalcoholis Steatohepatitis: a study of 49 patients. Hum. pathol. 20, 594-8, (1989).
11. Marchesini G., Bugianesi E., Forlani G., Cerelli F., Lenzi M., Manini R., Natale S., Vanni E., et al. Nonalcoholic fatty Liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917-23, (2003).
12. Angulo P., Keach J.C., Batts K.P., Lindor K.D.: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30, 1356-6, (1999).
13. Dixon J.B., Bhathal P.S., O'Brien P.E.: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121, 91-100, (2001).
14. Younossi Z.M., Gramlich T., Matteoni C.A., Boparai N., McCullough A.J.: Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin gastroenterol Hepatol. 2, 262-5, (2004).
15. Choudhary J., Sanyal A.J.: Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin. Liver Dis. 8, 575-94, (2004).
16. Pessayre D., Mansouri A., Hauzi D., Formenty B.: Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 15(6), 367-73, (1999).
17. Leclercq I.A., Farrell G.C., Field J., Bell D., Gonzalez F.: Robertson G. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Investig. 10598, 1067-75, (2000).
18. Chitturi S., Farell G.C.: Etiopathogenesis of nonalcoholic steatohepatitis. Seminars in Liver Disease 21(1), 27-41, (2001).
19. Edmison J., McCullough A.J.L.: Pathogenesis of Non-alcoholic Steatohepatitis: Human Data Clin. Liver Dis. 11(1), 75-104, (2007).
20. Palmer M., Schaffer F.: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99(5), 1408-13, (1990).
21. Vajro P., Fontanella A., Perna C., Orso G., Tedesco M., De VincenZo A.: Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J. Pediatr. 125(2), 239-41, (1994).
22. Ueno T., Sugawara H., Sujaka K., Hashimoto O., Tsuji R., Tamaki S., Torimura T., Inuzuka S., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 27(1), 103-7, (1997).
23. Kugelmas M., Hill D.B., Vivian B., Marsano L., McClain C.J.: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38, 413-19, (2003).
24. Hickman I.J., Jonsson J.R., Prins J.B., Ash S., Purdie D.M., Clouston A.D., Powell E., Tilg, H., et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53(3), 413-9, (2004).
25. Huang M.A., Greenson J.K., Chao C., Anderson L., Peterman D., Jacobson J., Enick D., Lok A., et al. One-year intense nutritional counseling results in histological improvements in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 100(5), 1072-81, (2005).
26. Anderson T., Gluud C., Franzmann M.B., Christoffersen P.: Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol. 12 (2), 224-9, (1991).
27. Kraus R.M., Eckel R.H., Howard B., Appel L., Daniels S., Deckelbaum R., Erdman J., Jr, Kris-Etherton P., et al. AHA dietary guidelines: revision 2000. A statement for health care professionals from the nutrition committee of the American Heart Association. Stroke 31, 2751-66, (2000).
28. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch. Intern. Med. 158, 1855-67, (1998).
29. Harrison S.A, Ramrakhiani S., Brunt E.M., Anbari M., Cortesc, C., Bacon B.: Orlistat in the treatment of NASH: a case series. Am. J. Gastroenterol. 98(4), 926-30, (2003).
30. Sabuncu T., Nazligul Y., Karaoglanoglu M.: The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Romanian J. Gastroenterol. 98(4), 926-30, (2003).
31. Brolin R.E.: Bariatric surgery and long-term control of morbid obesity. JAMA 288, 2793-6, (2002).
32. Sjostrom L., Lindroos A.K., Peltonen M., Torgerson J., Bouchard C., Carlsson B., Dahlgren S., Larsson B., et al. Group SOSSS. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-93, (2004).
33. Dixon J.B., Bhathal P.S., Hughes N.R., O'Brien P.E.: Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 39, 1647-54, (2004).
34. Minassian C., Tarpin S., Mithieux G.: Role of glucose-6 phosphatase, glucokinase, and glucose-6-phos-phatase in liver insulin resistance and its correction by metformin. Biochem. Pharmacol. 55(8), 1213-9, (1998).
35. Arslanian S.A., Lewy V., Danadian K., Saad R.: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J. Clin. Endocrinol. Metab. 87(4), 1555-9, (2002).
36. Solomon S.S., Mishra S.K., Cwik C., Rajanna B., Postlethwaite A.E.: Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm. Metab. Res. 29(8), 379-82, (1997).
37. Marchesini G., Brii M., Bianchi G., Tomassetti S., Zoli M., Melchionda N.: Metformin in non-alcoholic steatohepatitis. Lancet 358, 893-4, (2001).
38. Schwimmer J.B., Middleton M.S., Deutsch R., Lavine J.: A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 21, 871-9, (2005).
39. Magalotti D., Marchesini G., Ramilli S.: Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig. Liver Dis. 36, 406-11, (2004).
40. Nair S., Diehl A.M., Wiseman M.: Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 20, 23-8, (2004).
41. Bugianesi E., Gentilcore E., Manini R.: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100, 1082-90, (2005).
42. Yki-Jarvinen H.: Thiazolidinediones. N. Engl. J. Med. 351(11), 1106-18, (2004).
43. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., Bacon B.R.: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008-17, (2003).
44. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., Doo E., Ghany M., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39, 188-96, (2004).
45. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., Balas B., Gastaldelli A., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355(22), 2297-307, (2006).
46. Nissen S.E., Wolski K.: Effect of rosiglitazone on the risk of mycocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-71, (2007).
47. Basaranoglu M., Acbay O., Sonsuz A.: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol. 31(2), 384, (1999).
48. Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23(6), 1464-7, (1996).
49. Kiyici M., Gulten M., Gurel S., Nak S.G., Dolar E., Savci G.: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17(12), 713-8, (2003).
50. Hatzitolios A., Savopoulos C., Lazaraki G., et al. Efficacy of omega-3 fatty acids, atarvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J. Gastrenterol. 23, 131-4, (2004).
51. Rallidis L.S., Drakoulis C.K., Parasi A.S.: Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 174, 193-6, (2004).
52. Dominguez E.G., Gisbert J.P.: A pilot study of atorvastatin treatment in dyslipedemic, non-alcoholic fatty liver patients. Alimen. Pharmacol. Ther. 23(11), 1643-1647, (2006).
53. Chalasani N.: Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41, 690-5, (2005).
54. Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A.: Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther. 15, 1667-72, (2001).
55. Lavine J.E.: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Peadiatrics. 136(6), 734-8, (2000).
56. Vajro P., Mandato C., Franzese A.: Vitamin treatment in paediatric obesity-related liver disease: a randomized study. J. Pediatr. Gastroenterol. Nutr. 38, 48-55, (2004).
57. Harrison S.A., Torgerson S., Hayashi P.: Vitamin E and Vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98(11), 2485-90, (2003).
58. rd. n editorial update for vitamin E. Ann. Intern. Med. 2005; 143: 143-5.
59. Abdelmalek M.F., Angulo P., Jorgensen R.A., Sylvastere P., Lindor K.; Betaine, A promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 96(9), 2711-7, (2001).
60. Gulbahar O., Karasu Z.A., Ersoz G.: Treatment of nonalcoholic steatohepatitis with N-acetylcysteine. Gastroenterology. 118, A1444, (2000).
61. Satapathy S.K., Garg S., Chauhan R., Malhotra V., Sakhuja V., Sharma B., Sarin S.: Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastrenterol. 99, 1946-52, (2004).
62. Adams L.A., Zien C.O., Angulo P., Lindor K.: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 2365-8, (2004).
63. Lirussi F., Azzalini L., Orlando S.: Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane. Database. Syst. Rev. 24 (1), (2007).
64. Kiyici M., Gulten M., Gurel S.: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17, 713-18, (2003).
65. Lindor K.D., Kowdley K.V., Heathcote E.J.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39, 770-8, (2004).
66. Vitale C., Mercuro G., Castiglioni C., Cornoldi A., Tulli A., Fini M.: Metabolic effects Oftelmisartan and locating in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 4, 6-14, (2005).
67. Sloniger J.A., Saengsirisuwan V., Diehl C.J., Kim J.S., Henriksen E.J.: Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG (mREN2)27 rats. Metabolism 54(12), 1659-68, (2005).
68. Scheen A.J.: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomized clinical trials. Diabetes Metab 30(6): 487-96, (2004).
69. Yokohama S., Yoneda M., Haneda M.: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with non alcoholic steatohepatitis. Hepatology 40, 1222-5, (2004).
70. Charatcharoenwitthaya P., Levy C., Angulo P.: Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int. 27(2), 220-6, (2007).
71. Capanni M., Calella F., Biagini M.R., Genise S., Raimondi L.: Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment. Pharmacol. Ther. 23(8), 1143-51, (2006).
72. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., Cummins A.G.: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor alpha in the pathogenesis of non alcoholic steatohepatitis. Gut 48(2), 206-11, (2001).
73. Solga S.F., Diehl A.M.: Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 38(5), 681-7, (2003).
74. Loguercio C., Federico A., Tuccillo C., Terracciano F., D'Auria M.V., De Simone C.: Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 39(6), 540-3, (2005).
75. Daubioul C.A., Horsmans Y., Lambert P., Danse E., Delzenne N.M.: Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur. J. Clin. Nutr. 59(5), 723-6, (2005).
76. Morito Y., Ueno T., Sasaki N., Tateishi Y., Nagata E., Kage M.: Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 52 (65), 1338-43, (2005).
77. Despres J.P., Golay A., Sjostrom L.: Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353(20), 2121-34, (2005).
78. Pershadsingh H.A.: Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists: In the Treatment of Type 2 Diabetes Mellitus and the metabolic Syndrome. Treat Endocrinol. 5(2), 89-99, (2006).
79. Kadayifci A., Merriamn R., Bass N.: Medical treatment of non-alcoholic steatohepatitis. Clin. Liver Dis. 11(1), 119-140, (2007).